Figure 2
The number of drugs developed with a $1 billion dollar investment. We used the cost to launch figures to estimate how many drugs could be developed assuming all programs were successful, and no programs suffered any delays or problems. The comparison is a relative comparison. We did not include any risk factor for the failure of programs, and if they had been added, the surrogate based program number would have been relatively higher than the clinical endpoint driven programs.